The international surgical journal with global reach

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020; 395: 1558-1568.

Published: 22nd July 2020

Authors: Zimmer S, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C et al.

Conclusion

The study included 167 patients followed for a median of 28 months. Adjuvant nivolumab, alone or in combination with ipilumumab, improved 2-year recurrence-free survival (42 per cent and 70 per cent, respectively) compared to placebo (14 per cent). Treatment-related adverse events were higher with combined therapy.

Pubmed Link